Indonesia Holds Rate Steady to Back Rupiah Amid Market Jitters
Indonesia's central bank kept its key interest rate unchanged for a second straight month, acting to safeguard the rupiah in the face of rising capital outflows due to global trade turmoil and domestic policy risks.
Bank Indonesia kept the BI-Rate at 5.75% on Wednesday as predicted by 27 of 38 economists in a Bloomberg News survey. The other 11 expected a quarter-point cut. The central bank also maintained its 2025 economic growth forecast at 4.7%-5.5% and kept its inflation target at 1.5%-3.5%.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025
Data from the ongoing Phase 2a study shows a 100% disease control rate with 45% of patients with advanced cutaneous T-cell lymphoma achieving an objective response: One complete response, three partial responses, and five stable diseases in nine evaluable patients so far Robust immune activation supporting clinical activity observed Study continues to enroll patients; dose optimization phase to follow. LUND, SE / / June 12, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated positive data from the ongoing Phase 2a dose expansion study of BI-1808 monotherapy in cutaneous T-cell lymphoma (CTCL). The data will be presented in a poster at the European Hematology Association (EHA) 2025 congress, June 12-15 in Milan, Italy. As of the cut-off date May 15, 2025, data showed a 100% disease control rate in nine evaluable patients with CTCL. Forty-five percent of these patients achieved an objective response, with one patient achieving a complete response (CR), three achieving a partial response (PR), and five exhibiting stable disease (SD). Additionally, two patients with peripheral T-cell lymphoma (PTCL) were evaluable, of which one showed a PR, while the other showed SD. Overall, BI-1808 monotherapy demonstrates promising clinical activity and robust immune BI-1808 was well tolerated, with all treatment-related adverse events reported as mild or moderate (Grade 1-2). Notably, no Grade 3 or higher adverse events were observed. Transient disease flares, including skin peeling, erythema, and pruritus during the first weeks of treatment, were observed and shown to be associated with the BI-1808 immunologic mechanism. These flares coincide with regulatory T cell depletion and influx of CD8+ T cells into the skin, indicating on-target immune activation. Immunofluorescence multiplexing, starting at week 5, further confirmed increased CD8+ T cell infiltration and elevated granzyme B, supporting the drug candidate's mechanism of action. "These results reinforce the potential of BI-1808 as a novel immune-modulating therapy for CTCL," said Martin Welschof, Chief Executive Officer of BioInvent. "The early and sustained immune activation observed, combined with a favorable safety profile and 100% disease control rate, support the value of our anti-Tumor Necrosis Factor Receptor 2 (TNFR2) approach. We believe that these early Phase 2a data represent a meaningful milestone in our mission to deliver transformative therapies for difficult-to-treat patients, and we look forward to advancing BI-1808 into later-stage studies." Details of the poster:Title: Robust Single Agent Activity of BI-1808, a Tumor Necrosis Factor Receptor 2 (TNFR2) Blocker/Depleter, in Cutaneous T Cell Lymphoma (CTCL) PatientsSession Date and Time: June 13, 2025, 6:30-7:30 pm CESTSession Title: Poster Session 1Lead Author: Stefan K. Barta, University of Pennsylvania Hospital, Philadelphia, PA, USAAbstract Number: PF961 The poster will be posted to the Scientific Publications section of the company website ( ). The safety and preliminary efficacy of BI-1808 monotherapy are currently being evaluated in a sub-cohort (Part A) of the ongoing Phase 2a ( NCT04752826 ) study in patients with T-cell lymphomas, including CTCL. The study is expected to enroll 20 patients at a signal-seeking dose, after which a dose optimization phase is planned to be initiated. In April 2025, BioInvent received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for BI-1808 for the treatment of CTCL and in March 2025, Orphan Drug Designation was received from the same agency for BI-1808 in T-cell lymphoma (TCL). About BI-1808The anti-TNFR2 antibody BI-1808 is part of BioInvent's tumor-associated regulatory T cells (Treg)-targeting program. TNFR2 is particularly upregulated on Tregs of the tumor microenvironment and has been shown to be important for tumor expansion and survival, representing a new and promising target for cancer immunotherapy. BI-1808 is a first-in-class drug candidate in clinical development for the treatment of solid tumors and blood cancer. BI-1808 has shown single agent activity and excellent tolerability in an ongoing Phase 2a study and signs of efficacy and favorable safety profile in combination with pembrolizumab in the ongoing Phase 1/2a study. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at . For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-12 09:00 CEST. Attachments BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025 SOURCE: BioInvent International View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Major Company Giving Employees $1,000 LEGO Allowance
Companies will often give their employees perks and extra benefits. These can include discounts, free items and even vacations. One major company is offering a benefit to employees that has rarely been seen, but is sure to make those who work at other companies slightly jealous. Professional services firm Deloitte offers its employees an annual well-being subsidy of up to $1,000. Employees are allowed to use that subsidy on a variety of items, and recent guidelines have added "Legos and puzzles," according to Business Insider. The company has offered the subsidy for several years, and recently upped the amount from $500. It's offered to most partners and salaried workers at the company, but interns, contractors and those on a leave of absence aren't eligible. "Most of the responses are things like 'Lego?!?!? Finally!' or jokes about how they can now rationalize buying the coveted Millennium Falcon Star Wars Lego set," one employee told BI. Another employee was happy to see Legos added, and said that spending a few hours to build a set "is a great stress reliever." Many employees were reportedly happy that the company was thinking outside of the box when considering what employees could or would spend the subsidy on. The popular building bricks are just one of the new additions to the policy. Other items and categories added to the subsidy list this year include kitchenware and kitchen appliances, spa services, personal fans and ergonomic pillows. The subsidy is a great benefit for working at Deloitte, one of the biggest consulting firms in the world. The work is often demanding, with employees reporting that they work an average of 55 hours per week. "Since you are constantly changing projects and working with different leaders, achieving work-life balance is sadly always variable," one employee said while speaking to Women in Business. "Sometimes you get it, sometimes you really don't." Ernst & Young, another of the Big Four consulting and professional service firms, offers a similar subsidy that allows employees to purchase items like game consoles and mattresses. Deloitte had nearly 173,000 employees last year and generated over $33 billion in revenue. Major Company Giving Employees $1,000 LEGO Allowance first appeared on Men's Journal on Jun 12, 2025
Yahoo
16 hours ago
- Yahoo
Deloitte's US employees can now buy $1,000 of Lego on the company's dime to boost their well-being
Deloitte US offers its employees a $1,000 well-being subsidy to spend on things like gym memberships. The policy was updated in June to add several new items to the approved list, including Lego sets. "Lego?!?!? Finally!" was the reaction in internal chats, one Deloitte employee told Business Insider. Surviving the gruelling hours and high demands of a job in consulting isn't easy. Deloitte has a new solution to help its employees handle the stress: Lego. The Big Four professional services firm has updated its long-running well-being subsidy program to include "Legos and puzzles" on a list of items that Deloitte will reimburse, internal policy documents seen by Business Insider show. The firm has long offered eligible US staff an annual subsidy to spend on one or a combination of subscriptions, equipment, and experiences. In 2021, the firm doubled the allowance from $500 to $1,000, an internal webpage shows. The subsidy is meant to "empower and support your journey toward thriving mentally, physically, and financially and living your purpose," the policy documents say. Most partners and salaried workers are offered the benefit. Interns, contracted professionals, and employees on a leave of absence are not eligible. One Deloitte US employee told BI that people were discussing the new updates in internal team chats. "Most of the responses are things like 'Lego?!?!? Finally!' or jokes about how they can now rationalize buying the coveted Millennium Falcon Star Wars Lego set," the employee said. Lego's most expensive set, the Star Wars Ultimate Collector Series Millennium Falcon, costs $850, leaving Deloitte workers with a small allowance left over to spend on other qualifying items like fencing classes or neck pillows. A second Deloitte employee told BI that they see the subsidy as a nod of appreciation from the company for dealing with the stress and frustrations of their job. "This makes a huge difference! I personally like to think of what I need/want for the next subsidy. I have been able to upgrade my workspace, and it helps with the work intake," the person said. They added that Lego was receiving a lot of attention in the office, as it was a departure from the basics. "Knocking out a four-hour Lego build in under two hours is a great stress reliever," the employee said. Lego is just one of several new additions to the list of approved items, which were updated on June 1, the start of Deloitte's financial year. Under a section titled "what's new for FY26" are kitchenware and kitchen appliances (e.g., blender, refrigerator), spa services like facials and body treatments, personal portable cooling fans, and ergonomic, cooling, and sleeping pillows. Employees can also spend the subsidy on items like office furniture, gym equipment, financial support apps, fitness classes, and gaming consoles, including the Nintendo Switch and PlayStation. Deloitte US did not respond to a request for comment from BI. Not all are as positive about the subsidy program, with one Deloitte US employee telling BI they think it is only given "because of how much this job sucks." The US division of Deloitte has faced a challenging period after its contracts with the government came under scrutiny as part of the White House Office's efforts to cut federal spending. By April, at least 127 of the firm's government contracts had been cut or modified, according to BI's analysis of data on the DOGE website. That month, Deloitte Consulting CEO Jason Salzetti said in an internal meeting that a "small percentage" of workers in the firm's government division would be laid off. Employees told BI that DOGE's actions had shifted the climate at Deloitte. The US branch of Deloitte had 172,800 employees in 2024, when it last reported head count. Have a tip? Contact this reporter via email at pthompson@ or Signal at Polly_Thompson.89. Use a personal email address and a nonwork device; here's our guide to sharing information securely. Read the original article on Business Insider
